Modified BiP, IRL201805 inhibits osteoclastogenesis in monocytes derived from rheumatoid arthritis patients
The study demonstrates that the modified BiP protein IRL201805 effectively inhibits RANKL-induced osteoclastogenesis in monocytes from rheumatoid arthritis patients by preferentially suppressing over 2,000 genes involved in differentiation and cell fusion, including those in the RANKL/RANK signaling pathway.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Rheumatoid arthritis is a condition where the body's immune system mistakenly attacks the joints, causing pain, swelling, and stiffness. Over time, this inflammation does more than just hurt; it eats away at the bone. The culprits behind this bone destruction are specialized cells called osteoclasts. Think of these cells as the body's natural demolition crew, designed to break down old bone so new bone can take its place. In a healthy person, this process is balanced, but in rheumatoid arthritis, the demolition crew goes into overdrive, tearing down bone faster than it can be rebuilt. This leads to the severe joint damage and deformity that defines the disease. While current treatments are very good at calming the immune system and reducing inflammation, they do not always stop the bone erosion completely, and some patients do not respond well to them. Scientists are therefore looking for new ways to specifically target these bone-destroying cells without disrupting the rest of the immune system.
A team of researchers at the University of Glasgow and Revolo Biotherapeutics has been investigating a new biological therapy called IRL201805. This substance is a laboratory-made version of a natural protein found in the body that usually helps cells cope with stress. Previous studies had shown that this protein could stop bone-destroying cells from forming in healthy people, but it was unclear if it would work on the highly active, inflamed cells found in patients with rheumatoid arthritis. The researchers wanted to know if this therapy could calm the demolition crew in the specific environment of a rheumatoid arthritis patient and, if so, how it managed to do it.
To find the answer, the scientists took blood samples from patients with active rheumatoid arthritis and from healthy volunteers. They isolated a specific type of white blood cell from the blood, known as a monocyte, which is the precursor that turns into a bone-destroying cell. In the laboratory, they encouraged these cells to mature into osteoclasts using natural signals that tell them to start working. They then treated some of these cultures with the new therapy, IRL201805, while leaving others untreated to serve as a comparison. The results were striking. In the cultures treated with the therapy, the number of fully formed bone-destroying cells dropped dramatically, from an average of 777 in untreated samples to just 102 in treated samples. This happened whether the cells came from a healthy person or a patient with rheumatoid arthritis. Even more surprisingly, the researchers found that they only needed to expose the cells to the therapy once, for a short period at the beginning of the experiment, to stop the cells from forming. This suggests that the treatment acts very early in the process, essentially giving the cells a signal to stop before they ever become dangerous.
To understand exactly how this signal worked, the researchers looked at the genetic instructions inside the cells, a process known as RNA sequencing. They compared the genes being read in the treated cells against those in the untreated cells. They discovered that the therapy caused massive changes in the genetic activity of the cells from rheumatoid arthritis patients, altering the instructions for thousands of genes. In contrast, the changes in cells from healthy people were much smaller. The therapy appeared to specifically target the main pathway that tells these cells to form and work. It turned down the volume on the genes that drive the cells to become bone destroyers and turned up the volume on genes that act as brakes, stopping the process. Crucially, it interfered with a key chemical switch inside the cell that is often stuck in the "on" position in rheumatoid arthritis, effectively resetting the cell's behavior.
The study also revealed that the therapy does more than just stop the cells from forming; it seems to stop them from fusing together. Bone-destroying cells are unique because they are large and contain multiple nuclei, formed when smaller precursor cells merge together. The researchers found that the therapy blocked the genes responsible for this fusion, meaning the cells remained small and single, unable to perform their destructive work. This dual action—stopping the cells from forming and preventing them from joining together—offers a powerful way to protect the bone. The findings suggest that this therapy could be a valuable tool for rheumatoid arthritis patients, particularly because it targets the specific biological errors that occur in their disease, rather than just broadly suppressing the immune system. While further testing is needed to see how this works in the human body over time, the laboratory results provide a clear and promising picture of a new way to protect joints from the inside out.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.